Researchers at UCSF, funded in part by the Chan Zuckerberg Biohub, have generated a modular and effective CRISPRi system for the genetic dissection of non-model bacteria.
The vast majority of bacteria, including human pathogens and microbiome species, lack genetic tools needed to associate genes with phenotypes. A method of gene disruption, clustered regularly interspaced short palindromic repeats interference (CRISPRi), enables the robust silencing of target genes by interfering with gene transcription. CRISPRi has demonstrated utility in species ranging from bacteria to humans. However, the difficulty of establishing robust genetic tools, such as CRISPRi, in non-model bacteria has profoundly limited our understanding of the contributions of genes and gene networks to bacterial physiology and pathogenicity.
The inventors have developed Mobile-CRISPRi, a suite of modular CRISPRi systems for use in non-model bacterial systems. Mobile-CRISPRi can be stably integrated into diverse bacterial species and used in combination with organism-specific genetic libraries and tools. Mobile-CRISPRi modules achieve transfer and genomic integration by distinct mechanisms, while ensuring a specified orientation and without gene disruption. Importantly, genomic integration is stable for more than 50 generation, even in the absence of selection. The inventors demonstrate the efficacy and applicability of Mobile-CRISPRi in drug-gene synergy studies in several pathogenic bacteria.
Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 12,018,258 | 06/25/2024 | 2019-228 |
CRISPRi, genome integration, genetic dissection, bacterial pathogenesis, non-model bacteria